Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global protease inhibitors market is expected to grow at a CAGR of 4.30% in the forecast period of 2023-2028 driven by the increasing prevalence of viral diseases such as HIV/AIDS and hepatitis C.
Protein slicing or cutting enzymes are known as proteases. The function of protease is inhibited by protease inhibitor, which stops the viral replication. The molecules known as protease inhibitors have numerous uses. In some circumstances, the term protease inhibitor (PI) refers to a particular class of medication that is predominantly used to treat HIV/AIDS and hepatitis. In addition to antiviral medications, these protease inhibitors can be utilised to treat diabetes and cancer. For protein purification or cell/tissue extraction, a variety of protease inhibitors can be utilised as reagents.
Based on disease indication, the market is segmented into HIV/ AIDS, hepatitis C, alpha-1 antitrypsin deficiency, and hereditary angioedema (HAE), among others. The market, on the basis of distribution channels is categorised into hospital pharmacies, retail pharmacies, and online. The regional markets for protease inhibitors can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global protease inhibitors market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
HIV/AIDS are growing in prevalence worldwide, and with no cure, effective treatments are highly in demand. Protease inhibitors are a class of antiretroviral medication used to treat HIV, resulting in the HIV/AIDS disease indication dominating the protease inhibitors market growth.
Protease inhibitors aim to lower the body's viral load—a measure of the amount of the HIV virus—to undetectable levels. Drugs called protease inhibitors stop the activity of protease enzymes. This stops the HIV life cycle by preventing protease enzymes from playing their function in enabling HIV to proliferate.
Use of protease inhibitors helps treat the symptoms of HIV, inhibit the spread of the virus, and prevent it from replicating. To properly treat HIV, protease inhibitors must be taken with other drugs. Almost all protease inhibitors require the addition of either ritonavir or cobicistat in order to be fully effective.
North America is anticipated to lead the global market for protease inhibitors during the forecast period. This can be attributed to factors including the region's high prevalence of HIV and chronic hepatitis C virus, and effective healthcare infrastructure that are anticipated to propel the market in North America.
The market in the Asia Pacific region is anticipated to expand at a fast rate during the forecast period due to factors like a high prevalence of chronic diseases, ageing population, and the growing concentration of pharmaceutical companies in Asia Pacific. Additionally, a rise in awareness of anti-retroviral drugs across continents like Asia is stimulating the global protease inhibitors market.
Thermo Fisher Scientific, a provider of scientific equipment, reagents and consumables, and software services, is based in the United States. The 1956-founded business provides goods and services that benefit clients all over the world in hospitals and laboratories, on assembly lines, and in the field. It generates around USD 40 billion in annual revenue and is a driving force in the research, healthcare, industrial, and application markets.
Boehringer Ingelheim International GmbH, a German-based pharmaceutical business creates, produces, and sells medicines, parasiticides, vaccines, and treatments for unmet medical needs. It provides a wide range of products, including biopharmaceuticals, animal health care items, and treatments for human ailments. The company's goods are used, among other things, to treat diseases of the immune system, central neurological system, cardiometabolic system, respiratory system, retina, and various cancers.
Bristol-Myers Squibb Company, a speciality biopharmaceutical company founded in 1887 with its headquarters in the United States, specialises in the discovery, development, licencing, manufacturing, marketing, distribution, and sale of medications and other healthcare products to patients with serious diseases. Its main areas of focus are cardiovascular, cancer, immunology, and fibrotic therapeutic projects. The business provides its goods to wholesalers, retail pharmacies, hospitals, healthcare workers, and governmental organisations all around the world.
Other market players include Johnson & Johnson Services, Inc. and KalVista Pharmaceuticals, Inc., among others.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Disease Indication||
|Breakup by Distribution Channels||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
7 Industry Opportunities and Challenges
8 Global Protease Inhibitors Market Analysis
8.1 Key Industry Highlights
8.2 Global Protease Inhibitors Historical Market (2018-2022)
8.3 Global Protease Inhibitors Market Forecast (2023-2028)
8.4 Global Protease Inhibitors Market by Disease Indication
8.4.1 HIV/ AIDS
126.96.36.199 Market Share
188.8.131.52 Historical Trend (2018-2022)
184.108.40.206 Forecast Trend (2023-2028)
8.4.2 Hepatitis C
220.127.116.11 Market Share
18.104.22.168 Historical Trend (2018-2022)
22.214.171.124 Forecast Trend (2023-2028)
8.4.3 Alpha-1 Antitrypsin Deficiency
126.96.36.199 Market Share
188.8.131.52 Historical Trend (2018-2022)
184.108.40.206 Forecast Trend (2023-2028)
8.4.4 Hereditary Angioedema (HAE)
220.127.116.11 Market Share
18.104.22.168 Historical Trend (2018-2022)
22.214.171.124 Forecast Trend (2023-2028)
8.5 Global Protease Inhibitors Market by Distribution Channels
8.5.1 Hospital Pharmacies
126.96.36.199 Market Share
188.8.131.52 Historical Trend (2018-2022)
184.108.40.206 Forecast Trend (2023-2028)
8.5.2 Retail Pharmacies
220.127.116.11 Market Share
18.104.22.168 Historical Trend (2018-2022)
22.214.171.124 Forecast Trend (2023-2028)
126.96.36.199 Market Share
188.8.131.52 Historical Trend (2018-2022)
184.108.40.206 Forecast Trend (2023-2028)
8.6 Global Protease Inhibitors Market by Region
8.6.1 Market Share
220.127.116.11 North America
18.104.22.168 Asia Pacific
22.214.171.124 Latin America
126.96.36.199 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
188.8.131.52 United States of America
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
184.108.40.206 United Kingdom
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
220.127.116.11 Saudi Arabia
18.104.22.168 United Arab Emirates
22.214.171.124 South Africa
10 Market Dynamics
10.1 SWOT Analysis
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Thermo Fisher Scientific
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
11.2.2 Boehringer Ingelheim International GmbH
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
11.2.3 Bristol-Myers Squibb Company
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
11.2.4 Johnson & Johnson Services, Inc.
220.127.116.11 Company Overview
18.104.22.168 Product Portfolio
22.214.171.124 Demographic Reach and Achievements
11.2.5 KalVista Pharmaceuticals, Inc.
126.96.36.199 Company Overview
188.8.131.52 Product Portfolio
184.108.40.206 Demographic Reach and Achievements
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Protease Inhibitors Market: Key Industry Highlights, 2018 and 2028
2. Global Protease Inhibitors Historical Market: Breakup by Disease Indication (USD Million), 2018-2022
3. Global Protease Inhibitors Market Forecast: Breakup by Disease Indication (USD Million), 2023-2028
4. Global Protease Inhibitors Historical Market: Breakup by Distribution Channels (USD Million), 2018-2022
5. Global Protease Inhibitors Market Forecast: Breakup by Distribution Channels (USD Million), 2023-2028
6. Global Protease Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2022
7. Global Protease Inhibitors Market Forecast: Breakup by Region (USD Million), 2023-2028
8. North America Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
9. North America Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Europe Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
11. Europe Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Asia Pacific Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
13. Asia Pacific Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Latin America Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
15. Latin America Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Middle East and Africa Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
17. Middle East and Africa Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Global Protease Inhibitors Market Structure
The market for protease inhibitors is projected to grow at a CAGR of 4.30% between 2023 and 2028.
The major drivers of the protease inhibitors market include the rising prevalence of viral disorders including HIV/AIDS and hepatitis C and the growing public awareness of anti-retroviral therapy and cancer treatment.
The extensive research and development efforts, increase in the number of pharmaceutical manufacturers, increase in the incidence of lifestyle illnesses, approval of protease inhibitors (PI) medications, efficient health care infrastructure, and a growing ageing population are the key industry trends propelling the growth of the market.
The major players in the industry are Thermo Fisher Scientific, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., and KalVista Pharmaceuticals, Inc., among others.
Tubers and plant seeds are abundant with protease inhibitors. Although significant levels of proteinase inhibitors are frequently seen in many plants belonging to the Solanaceae family, proteinase inhibitors are present in plants from a number of systematic groups.
The protease inhibitors approved by the United States Food and Drug Administration (FDA) include: saquinavir mesylate (Invirase), tipranavir (Aptivus), darunavir ethanolate (Prezista), atazanavir sulfate (Reyataz), fosamprenavir calcium (Lexiva), indinavir sulfate (Crixivan), ritonavir (Norvir), and nelfinavir mesylate (Viracept).
Protease inhibitors are specifically antiviral medications that are used to treat targeted viruses such as HIV (human immunodeficiency virus).
Protease inhibitors are utilised to protect protein samples from the proteases' digestive activity, which begins during the isolation procedure. They are used in order to avoid imminent spontaneous breakdown of protein samples and cell lysates.
Some of the common diseases are treated with protease inhibitors are HIV/ AIDS, hepatitis C, alpha-1 antitrypsin deficiency, and hereditary angioedema (HAE), among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.